A new subgroup analysis showed patients with severe, eosinophilic asthma administered reslizumab (Cinqair) over 12 months had meaningful improvement in outcomes including pulmonary function and disease-related healthcare resource use.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045